Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10

Larry M. Rose, Angelo H. Gunasekera, Sally J. DeNardo, Gerald L Denardo, Claude F. Meares

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

The selectivity of Lym-1 for malignant B lymphocytes makes this monoclonal antibody a promising candidate for the delivery of toxic agents to malignant B cells. The original immunogen used for the development of Lym-1 was Raji Burkitt's lymphoma cell nuclei [Epstein A.L., Marder R.J., Winter J.N., Stathopoulos E., Chen F.M., Parker J.W., Taylor C.R. (1987) Cancer Res 47: 830]. The Lym-1 antigen was characterized at that time as a polymorphic HLA-DR variant. We prepared an affinity column using immobilized Lym-1 to isolate the Lym-1 antigen from Raji cell lysate. Immunological characterization of the immunoaffinity-purified Lym-1 antigen on Western blots led to the conclusion that the antigen is the β chain of HLA-DR10. This was confirmed by Edman sequencing of the isolated polypeptide chain. Western blots further show that the Lym-1 epitope is only recognized if the β chain disulfide bonds are intact. These results imply that Lym-1 binds a discontinuous epitope on the β chain of HLA-DR10.

Original languageEnglish (US)
Pages (from-to)26-30
Number of pages5
JournalCancer Immunology Immunotherapy
Volume43
Issue number1
DOIs
StatePublished - 1996

Fingerprint

Epitopes
Lymphoma
Light
Antigens
Antibodies
B-Lymphocytes
Far-Western Blotting
Burkitt Lymphoma
Poisons
HLA-DR Antigens
Cell Nucleus
Disulfides
Western Blotting
Monoclonal Antibodies
Peptides
HLA-DR10 antigen
Neoplasms

Keywords

  • B cell lymphocytic cancer antigen
  • HLA-DR10
  • Lym-1
  • Radioimmunotherapy
  • Tumor-selective antibodies

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Oncology

Cite this

Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10. / Rose, Larry M.; Gunasekera, Angelo H.; DeNardo, Sally J.; Denardo, Gerald L; Meares, Claude F.

In: Cancer Immunology Immunotherapy, Vol. 43, No. 1, 1996, p. 26-30.

Research output: Contribution to journalArticle

Rose, Larry M. ; Gunasekera, Angelo H. ; DeNardo, Sally J. ; Denardo, Gerald L ; Meares, Claude F. / Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10. In: Cancer Immunology Immunotherapy. 1996 ; Vol. 43, No. 1. pp. 26-30.
@article{da5b145c072847378c555400937e68ab,
title = "Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10",
abstract = "The selectivity of Lym-1 for malignant B lymphocytes makes this monoclonal antibody a promising candidate for the delivery of toxic agents to malignant B cells. The original immunogen used for the development of Lym-1 was Raji Burkitt's lymphoma cell nuclei [Epstein A.L., Marder R.J., Winter J.N., Stathopoulos E., Chen F.M., Parker J.W., Taylor C.R. (1987) Cancer Res 47: 830]. The Lym-1 antigen was characterized at that time as a polymorphic HLA-DR variant. We prepared an affinity column using immobilized Lym-1 to isolate the Lym-1 antigen from Raji cell lysate. Immunological characterization of the immunoaffinity-purified Lym-1 antigen on Western blots led to the conclusion that the antigen is the β chain of HLA-DR10. This was confirmed by Edman sequencing of the isolated polypeptide chain. Western blots further show that the Lym-1 epitope is only recognized if the β chain disulfide bonds are intact. These results imply that Lym-1 binds a discontinuous epitope on the β chain of HLA-DR10.",
keywords = "B cell lymphocytic cancer antigen, HLA-DR10, Lym-1, Radioimmunotherapy, Tumor-selective antibodies",
author = "Rose, {Larry M.} and Gunasekera, {Angelo H.} and DeNardo, {Sally J.} and Denardo, {Gerald L} and Meares, {Claude F.}",
year = "1996",
doi = "10.1007/s002620050299",
language = "English (US)",
volume = "43",
pages = "26--30",
journal = "Cancer Immunology, Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "1",

}

TY - JOUR

T1 - Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10

AU - Rose, Larry M.

AU - Gunasekera, Angelo H.

AU - DeNardo, Sally J.

AU - Denardo, Gerald L

AU - Meares, Claude F.

PY - 1996

Y1 - 1996

N2 - The selectivity of Lym-1 for malignant B lymphocytes makes this monoclonal antibody a promising candidate for the delivery of toxic agents to malignant B cells. The original immunogen used for the development of Lym-1 was Raji Burkitt's lymphoma cell nuclei [Epstein A.L., Marder R.J., Winter J.N., Stathopoulos E., Chen F.M., Parker J.W., Taylor C.R. (1987) Cancer Res 47: 830]. The Lym-1 antigen was characterized at that time as a polymorphic HLA-DR variant. We prepared an affinity column using immobilized Lym-1 to isolate the Lym-1 antigen from Raji cell lysate. Immunological characterization of the immunoaffinity-purified Lym-1 antigen on Western blots led to the conclusion that the antigen is the β chain of HLA-DR10. This was confirmed by Edman sequencing of the isolated polypeptide chain. Western blots further show that the Lym-1 epitope is only recognized if the β chain disulfide bonds are intact. These results imply that Lym-1 binds a discontinuous epitope on the β chain of HLA-DR10.

AB - The selectivity of Lym-1 for malignant B lymphocytes makes this monoclonal antibody a promising candidate for the delivery of toxic agents to malignant B cells. The original immunogen used for the development of Lym-1 was Raji Burkitt's lymphoma cell nuclei [Epstein A.L., Marder R.J., Winter J.N., Stathopoulos E., Chen F.M., Parker J.W., Taylor C.R. (1987) Cancer Res 47: 830]. The Lym-1 antigen was characterized at that time as a polymorphic HLA-DR variant. We prepared an affinity column using immobilized Lym-1 to isolate the Lym-1 antigen from Raji cell lysate. Immunological characterization of the immunoaffinity-purified Lym-1 antigen on Western blots led to the conclusion that the antigen is the β chain of HLA-DR10. This was confirmed by Edman sequencing of the isolated polypeptide chain. Western blots further show that the Lym-1 epitope is only recognized if the β chain disulfide bonds are intact. These results imply that Lym-1 binds a discontinuous epitope on the β chain of HLA-DR10.

KW - B cell lymphocytic cancer antigen

KW - HLA-DR10

KW - Lym-1

KW - Radioimmunotherapy

KW - Tumor-selective antibodies

UR - http://www.scopus.com/inward/record.url?scp=0029851182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029851182&partnerID=8YFLogxK

U2 - 10.1007/s002620050299

DO - 10.1007/s002620050299

M3 - Article

C2 - 8917632

AN - SCOPUS:0029851182

VL - 43

SP - 26

EP - 30

JO - Cancer Immunology, Immunotherapy

JF - Cancer Immunology, Immunotherapy

SN - 0340-7004

IS - 1

ER -